Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: A randomised trial

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Singh, Dave ^a   Worsley, Sally ^b   Zhu, Chang Qing ^b   Hardaker, Liz ^b   Church, Alison ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; UMECLIDINIUM PLUS VILANTEROL; BRONCHODILATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; QUINUCLIDINE DERIVATIVE; UMECLIDINIUM;

ADULT; ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE ASSESSMENT; RHINOPHARYNGITIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITION DYSPNEA INDEX; DRUG EFFECTS; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE DRUG COMBINATION; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; TREATMENT OUTCOME;

EID: 84939535711     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0092-1     Document Type: Article

References (21)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html (2014). Accessed 17 Dec 2014.
2. Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889-905.
3. Singh D. New combination bronchodilators for COPD: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79:695-708.
4. Anoro EU summary of product characteristics, 16 May 2014. http://www.medicines.ie/medicine/16007/SPC/ANORO+55+micrograms+22+micrograms+inhalation+powder,+pre-dispensed/ (2014). Accessed 17 Dec 2014.
5. ANORO US prescribing information, May 2014. https://www.gsksource.com/gskprm/htdocs/documents/ANORO-ELLIPTA-PI-MG.PDF (2014). Accessed 17 Dec 2014.
6. Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145:981-91.
7. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538-46.
8. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171-8.
9. Seretide EU summary of product characteristics. http://www.medicines.org.uk/emc/medicine/2317/SPC/Seretide+100,+250,+500+Accuhaler (2013). Accessed 17 Dec 2014.
10. Singh D, Worsley S, Zhu C-Q, Hardaker L, Church A. Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Eur Respir J. 2014;44 Suppl 58:P290.
11. World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. http://www.wma.net/en/30publications/10policies/b3/index.html (2008). Accessed 17 Dec 2014.
12. International Conference on Harmonisation Tripartite Guideline: Guidance for Good Clinical Practice E6 (R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (1996). Accessed 17 Dec 2014.
13. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium monotherapy in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43:72-81.
14. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
15. Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472-86.
16. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008;134:255-62.
17. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51-60.
18. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161.
19. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775.
20. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332-8.
21. Yawn BP, Raphiou I, Hurley JS, Dalal AA. The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:165-78.